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We aimed to evaluatemineralocorticoid receptor (MR) expression in rat bladder and the physiological role
of the MR-epithelial sodium channel (ENaC) pathway in controlling bladder function in 10e12-week-old,
male SpragueeDawley rats. First, we examined the mRNA expression of MR and localization of MR and
ENaC-a proteins in the urinary bladder. MR mRNA expression was observed in untreated-rat urinary
bladders, andMRandENaC-aproteinswere localized in the epithelium.Next, ratswere treatedwith vehicle
(controls) or ﬂudrocortisone (anMR agonist) for 3 days, and ENaC-a protein expression levels and bladder
function were evaluated on day 4. ENaC-a protein expression was signiﬁcantly higher in ﬂudrocortisone-
treated rats than in controls. In addition, cystometry was performed during intravesical infusion of saline
and amiloride (an ENaC inhibitor). While intercontraction intervals (ICIs) during saline infusion were
signiﬁcantly shorter in the ﬂudrocortisone group than in the controls, infusion of amiloride normalized the
ICIs in the ﬂudrocortisone group. However, no intra- or inter-group differences in maximum intravesical
pressurewere observed. Taken together, MR protein is localized in the rat urinary bladder epithelium, and
may regulate ENaC expression and bladder afferent input. The MR-ENaC pathway may be a therapeutic
target for ameliorating storage symptoms.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Overactive bladder syndrome (OAB) exhibits urinary urgency
and is typically accompanied by urinary frequency and nocturia
(1,2). Anticholinergic drugs are currently the most common treat-
ment for urinary incontinence and frequent urination in patients
with OAB (1). However, adverse events are often associated withizuho-ku, Nagoya 467-8601,
Kimura).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).anticholinergic drug use, including dry mouth, constipation, and
urination disorders, which can affect patient adherence (3,4). A
selective b3-adrenoceptor agonist, mirabegron, has recently been
approved for the treatment of OAB in several countries (5).
However, the treatment of some clinical cases has been difﬁcult
even by using this new drug. Therefore, a new therapeutic strategy
for storage dysfunction (including OAB) is needed.
The pathology of bladder dysfunction involves altered bladder
epithelial function (6), and a number of ion channels that are
expressed at the bladder epithelium are reportedly involved in
mechanosensation during bladder ﬁlling (e.g., TRPA1, TRPV4, or the
epithelial sodium channel [ENaC]) (7,8). In the rat urinary bladdernese Pharmacological Society. This is an open access article under the CC BY-NC-ND
MR (286 bp) 
Fig. 1. Reverse transcriptase-polymerase chain reaction and agarose gel electropho-
resis to analyze mineralocorticoid receptor expression in the rat urinary bladder.
Mineralocorticoid receptor (MR) mRNA expression was observed in the rat urinary
bladder. The kidney was used as the positive control, and the non-template control
(NTC) was used as the negative control.
S. Yamamoto et al. / Journal of Pharmacological Sciences 130 (2016) 219e225220epithelium, ENaC is known to play a key role in releasing ATP, which
is an important neurotransmitter for evoking detrusor contractions
in response to mechanical stretch in the storage phase (9).
Furthermore, among patients with bladder outlet obstruction and
benign prostatic hyperplasia, bladder mRNA levels of the ENaC a, b,
and g subunits is signiﬁcantly correlated with storage symptoms
using the International Prostate Symptom Score (IPSS) (10). In
addition, ENaC expression is regulated by mineralocorticoid re-
ceptors (MRs) in renal, colonic, and fetal lung alveolar type 2
epithelial cells (11,12); MRs are also expressed in the toad urinary
bladder (13). Aldosterone-bound to MRs regulated the unidirec-
tional transport of sodium from the mucosal phase to the serosal
phase via the activation of amiloride-blockade sodium channels
(13). However, to the best of our knowledge, no studies have shown
thatMRs are expressed in the bladder of rats or othermammals and
the MR-ENaC pathway plays a physiological role in regulating
bladder function. Therefore, the present study investigated
whether MRs are expressed in the rat urinary bladder, and whether
MR-ENaC signaling regulates bladder afferent nerve activity and
bladder function.2. Materials and methods
2.1. Animal and tissue preparation
We used 10e12-week-old male SpragueeDawley rats (SLC Inc.,
Shizuoka, Japan) for all experiments. The rats were kept in a
temperature- and humidity-controlled room, with a 12-h/12-h
light/dark cycle and free access to laboratory chow and normal
water. To prepare bladder tissue samples for the in vitro analyses,Fig. 2. Expression and localization of mineralocorticoid receptor protein and epithelial sodiu
2-phenylindole (DAPI)-positive nuclei. (A) Green staining indicates localization of the min
staining indicates localization of the epithelial sodium channel-a (ENaC-a) protein at the rthe rats were euthanized via excessive anesthesia, and their blad-
ders were collected for reverse transcriptase-polymerase chain
reaction (RT-PCR) and ﬂuorescent immunohistochemistry analysis.
All animal experiments were performed in accordance with the
Guiding Principles for the Care and Use of Laboratory Animals of
the Science and International Affairs Bureau of the Japanese Min-
istry of Education, Culture, Sports, Science and Technology. The
study design was reviewed and approved by the Ethics Committee
of Nagoya City University.
2.2. RT-PCR
Total RNA was extracted from the whole kidney without the
urothelium and the whole bladder by using the ISOGEN reagent
(Nippon Gene, Tokyo, Japan), according to the manufacturer's rec-
ommended protocol. The RNA concentration and quality were
measured via spectrophotometry at 260 nm and 280 nm. Then,1 mg
of total RNA was reverse transcribed using the ReverTra Ace-a-kit
(Toyobo, Osaka, Japan) according to the manufacturer's recom-
mended reaction protocol, with oligo (dT)20 as the primer. The
cDNA was mixed with AmpliTaq Gold DNA Polymerase in Buffer II
and MgCl2 (Applied Biosystems, Foster City, CA, USA), and the
solution was combined with two primers that are speciﬁc for the
MR gene: MR forward 50-GTGGACAGTCCTTTCACTACCG-30 and MR
reverse 50 -TGACACCCAGAAGCCTCATCTC-30. The speciﬁcity of these
primers was conﬁrmed by a BLAST search of the rat genome
database. The reaction mixtures were incubated at 95 C for 10min,
which was followed by 35 cycles of 95 C for 30 s, 60 C for 30 s, and
72 C for 30 s, and ﬁnally held at 72 C for 7 min. Non-template
control DNA was used as the negative control. The PCR products
were subjected to electrophoresis on a 2% agarose gel, then stained
with ethidium bromide and imaged under ultraviolet light. An
automated DNA sequencer was used to conﬁrm the DNA sequence
of the puriﬁed PCR products, using the sequence of the Nr3c2 gene
available in the online database.
2.3. Fluorescent immunohistochemistry
Extirpated urinary bladders and kidneys of untreated rats were
ﬁxed in 4% paraformaldehyde, which was replaced with 10%, 20%,
and 30% sucrose solutions for >12 h, and then frozen in an optimal
cutting temperature compound (Sakura Finetechnical Co., Ltd.,m channel-a protein in the rat urinary bladder. Blue staining indicates 40 ,6-diamidino-
eralocorticoid receptor (MR) protein at the rat urinary bladder epithelium. (B) Green
at urinary bladder epithelium. Scale bar ¼ 500 mm.
Table 1
Baseline data of the control and FC groups.
Control group FC group
Bladder-to-body weight ratio (mg/g) 0.28 ± 0.01 0.28 ± 0.02
Heart rate (beats per min) 358.0 ± 10.2 336.1 ± 9.2
Systolic blood pressure (mmHg) 127.2 ± 5.0 125.1 ± 3.5
Mean blood pressure (mmHg) 102.7 ± 3.8 104.4 ± 2.1
Diastolic blood pressure (mmHg) 90.6 ± 4.1 94.3 ± 1.7
Data are expressed as mean ± standard error. Three days following administration,
no statistically signiﬁcant differences were observed between the control and ﬂu-
drocortisone groups on day 4.
FC: Fludrocortisone.
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slides, and the slides were washed with phosphate buffered saline
(PBS) and then blocked with 5% skim milk in PBS for 1e2 h. After
washing with PBS, the sections were incubated for 30 min with a
goat anti-MR polyclonal antibody (1:50, Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA), or overnight with a rabbit anti-ENaC-a
polyclonal antibody (1:200, Bioss Inc., Woburn, MA, USA). Visuali-
zation of MR protein was performed for 30 min using the Alexa
Fluor 488 Donkey Anti-Goat IgG (Hþ L) antibody (1:250, Molecular
Probes, Eugene, OR, USA), and ENaC-a protein was visualized using
the Alexa Fluor 488 Goat Anti-Rabbit IgG (H þ L) antibody for
30 min (1:250, Molecular Probes). The nuclei were then stained for
3e5 min with Cellstain DAPI solution (Dojindo Laboratories,
Kumamoto, Japan).
Extirpated urinary bladders and kidneys of rats from Control, FC
and FC þ EPL groups were ﬁxed in 10% formaldehyde, which was
replaced with 70% ethanol, and the ﬁxed samples were then
embedded in parafﬁn. Serial sections (4-mm thickness) were
deparafﬁnized and rehydrated in an ethanol series, and antigens
were activated by the microwave method. The sections were
blocked with 5% skim milk in PBS for 1 h at room temperature and
incubated with a goat anti-MR polyclonal antibody (1:50) and
rabbit anti-ENaC-a polyclonal antibody (1:200), which were mixed
and diluted in Reagent 1 of IMMUNO SHOT (Cosmo Bio Co., Ltd.,
Tokyo, Japan) at 4 C overnight. Costaining of MR and ENaC-a was
performed for 30 min by using Alexa Fluor 488 Donkey Anti-Goat
IgG (H þ L) antibody (1:250) and Alexa Fluor 594 Donkey
Anti-Rabbit IgG (Hþ L) antibody (1:1000, Molecular Probes), which
were mixed and diluted in Reagent 2 of IMMUNO SHOT. The nuclei
were then stained with Cellstain DAPI solution (Dojindo Labora-
tories, Kumamoto, Japan).
Kidney tissues were used as a positive control, and the same







Fig. 3. Western blot analysis of the expression of epithelial sodium channel-a protein in
sentative immunoblots of epithelial sodium channel-a (ENaC-a) and b-actin proteins. (B) De
the ﬂudrocortisone (FC) group was signiﬁcantly upregulated, compared with the control grou
for the comparative analysis. Each bar indicates mean ± standard error values; n ¼ 3 in th2.4. The activated MR model
The rats were randomized into the control or ﬂudrocortisone
(FC, a potent MR agonist) groups. The FC group was treated orally
with FC (6 mg/kg/day) in 1% hydroxypropyl methylcellulose (Sig-
maeAldrich Japan, Tokyo, Japan), once daily for 3 days, based on
previous reports (14,15). The control group was treated with the
vehicle solution once daily for 3 days. After the 3-day treatment
period, the systemic arterial blood pressure and heart rate of the
rats in each group were measured using a noninvasive automatic
device (BP-98A-L, Softron, Tokyo, Japan), and the rats were main-
tained at 37 C during the measurements using a warmer (THC-31,
Softron). Each measurement was performed three times per rat
(while awake), and the mean value was used for analysis.2.5. Protein extraction and western blotting
After the 3-day treatment period, protein from the urinary
bladder of the rats was extracted using the PRO-PREP Protein
Extraction Solution (iNtRON Biotechnology Inc., Gyeonggi-do,
Korea), and the total protein concentration was quantiﬁed using
the BCA Protein Assay Reagent (Pierce Biotechnology, Rockford, IL,
USA). Samples containing 25 mg of total protein were separated via
10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis,
and were then transferred onto polyvinylidene diﬂuoride
membranes (ImmobilinTM;Millipore Corp., Bedford, MA, USA). The
membranes were blocked with 5% skim milk, incubated with the
primary rabbit anti-ENaC-a polyclonal antibody (1:500; Bioss Inc.,
Woburn, MA, USA) in Tris-buffered saline and Tween 20 (TBST), and
then incubated in TBST with the secondary anti-rabbit immuno-
globulin G (IgG), which was conjugated to horseradish peroxidase
(1:5000; GE Healthcare, Little Chalfont, UK). The protein bands
were visualized using ECL (GE Healthcare, Little Chalfont, UK) and
an ImageQuant LAS 4000 mini (GE Healthcare), the membranes
were washed with TBST, and the bound primary and secondary
antibodies were removed using Restore PlusWestern Blot Stripping
Buffer (Thermo Fisher Scientiﬁc, Waltham, MA, USA). Next, the
membranes were re-blockedwith 5% skimmilk, incubated with the
primary mouse anti-b-actin monoclonal antibody (1:2500; Sigma,
Saint Louis, MO, USA) in 5% skim milk, and then incubated with the
secondary anti-mouse IgG (1:5000; GE Healthcare). The protein
bands were visualized using ECL and ImageQuant LAS 4000 mini
(GE Healthcare). The band densities were quantiﬁed using ImageJ
software (National Institutes of Health, Bethesda, MD, USA), and


















the rat urinary bladder after three days of ﬂudrocortisone administration. (A) Repre-
nsitometric quantiﬁcation of the corresponding bands revealed that ENaC-a protein in
p. The mean expression level of ENaC-a protein in the control group was set to 1.0-fold
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Fig. 4. Cystometry after three days of ﬂudrocortisone administration. (A) Representative cystometrogram during intravesical infusion of saline and the subsequent amiloride (AMI)
treatment in the control and ﬂudrocortisone (FC) groups. (B) Results of the intercontraction intervals (ICI) analysis. The FC group exhibited signiﬁcantly shorter ICIs during the saline
infusion, compared with the control group. The subsequent infusion of amiloride signiﬁcantly prolonged the ICIs in the FC group, although it did not change the ICIs of the control
group. (C) The maximum intravesical pressure (MP) during saline and amiloride infusion in each group. No intra-group or inter-group changes in MPs were observed during
infusion of saline and amiloride. Each bar indicates mean ± standard error values (panels B, C); n ¼ 4 in the control group (vehicle administration), and n ¼ 7 in the FC group.
*P < 0.05 vs. control. ##P < 0.01 vs. saline. N.S., not signiﬁcant. Pves, intravesical pressure.
S. Yamamoto et al. / Journal of Pharmacological Sciences 130 (2016) 219e2252222.6. Bladder-ﬁlling cystometry
Under inhalational anesthesia with 3% isoﬂurane for induction
and 2% isoﬂurane for maintenance, the bladders of the rats were
exposed, and polyethylene-50 tubing (with holes in the sides) was
inserted into the bladder dome and sealed with 5e0 silk sutures.
The tubing was connected to a syringe pump that was connected to
a pressure transducer (UD5500, Dantec, Denmark), which allowed
for saline infusion, and cystometry was performed while the rats
were awake in a restraining cage. Each group received salineTable 2
Intercontraction intervals of control, FC, and FC þ EPL groups.
Group Intercontraction intervals (s)
Control 746.3 ± 73.8
FC 394.0 ± 60.5**
FC þ EPL 509.2 ± 110.1
Data are expressed as mean ± standard error.
** P < 0.01 vs. control group.
FC: ﬂudrocortisone, EPL: eplerenone.
n ¼ 5e11.(0.08 mL/min at room temperature), followed by 1 mM amiloride
hydrochloride hydrate (an ENaC inhibitor, 0.08 mL/min at room
temperature), for analysis of the intercontraction intervals (ICIs, the
time between two voiding contractions) and the maximum intra-
vesical pressure (MP, the maximum bladder pressure during a
micturition cycle). We then compared the intra- and inter-group
changes in ICI and MP during the amiloride and saline infusions.
In addition, to conﬁrm the involvement of MR in bladder function,
we used the MR-selective blocker eplerenone (EPL) (Tokyo Chem-
ical Industry, Tokyo, Japan). FC (6 mg/kg/day) with EPL (75 mg/kg/
day) in 1% hydroxypropyl methylcellulose (SigmaeAldrich Japan,
Tokyo, Japan) was orally administered to the rats once daily for 3
days, based on previous reports (16). Then, cystometry was per-
formed as described above. Rats did not move during cystometry;
hence, intravesical pressure was assumed equal to detrusor pres-
sure and residual urine volume was not be observed.2.7. Statistical analysis
The results are expressed as mean ± standard error of the mean.
The two-sided Student's t-test was used to compare the two

























Fig. 5. Western blot analysis of the expression of epithelial sodium channel-a protein
in the rat urinary bladder after three days of vehicle, ﬂudrocortisone or ﬂudrocortisone
plus eplerenone administration. (A) Representative immunoblots of epithelial sodium
channel-a (ENaC-a) and b-actin proteins. (B) Densitometric quantiﬁcation of corre-
sponding bands revealed that ENaC-a was signiﬁcantly upregulated in the ﬂu-
drocortisone (FC) group compared with the control group. Co-administration of EPL
with FC attenuated this effect of FC, although the difference was not statistically sig-
niﬁcant. The expression levels in the FC þ EPL group was not signiﬁcantly different
from those in the control group. The mean ENaC-a expression in the control group was
set to 1.0 for the comparative analysis. Each bar indicates mean ± standard error
values; n ¼ 4 in the control group (vehicle administration), n ¼ 7 in the FC group and
n ¼ 5 in the FC þ EPL group. *P < 0.05.
S. Yamamoto et al. / Journal of Pharmacological Sciences 130 (2016) 219e225 223intervention differences. Bonferroni multiple comparison tests
were used to determine signiﬁcantly differences between means.
Differences with a P-value of <0.05 were considered statistically
signiﬁcant.Fig. 6. Immunoﬂuorescent analysis of mineralocorticoid receptor protein and epithelial s
drocortisone or ﬂudrocortisone plus eplerenone administration. Blue, green, and red stain
receptor (MR) protein, and epithelial sodium channel-a (ENaC-a) protein, respectively, in
epithelium. The staining patterns were not altered between control, FC, and FC þ EPL grou3. Results
3.1. MR mRNA expression in the urinary bladder
Positive MR mRNA expression was observed in the kidney
(positive control) and rat urinary bladder, and no mRNA expression
was observed in the negative controls (Fig. 1). The base sequence of
the PCR product was identical to the previously reported sequence
(17).
3.2. MR and ENaC-a protein localization
As the ENaC-a subunit is critical for formation of functional
channels (18), we selected the ENaC-a protein as an indicator of
ENaC protein expression. Immunoﬂuorescence revealed that the
MR and ENaC-a proteins were clearly localized in the rat urinary
bladder epithelium (Fig. 2A, B). The positive (kidney tissue) and
negative (no primary antibodies) controls revealed that both pri-
mary antibodies were sensitive and speciﬁc (data not shown).
3.3. Baseline data for the control and FC groups
The control and FC groups had similar bladder-to-body weight
ratios, heart rates, systolic blood pressures, mean blood pressures,
and diastolic blood pressures on day 4 (Table 1).
3.4. The effect of FC on ENaC-a protein expression and bladder
function
After treatment with the vehicle or FC, we evaluated ENaC-a
expression in the rat urinary bladder via western blotting on day 4;
ENaC-a expression was higher in the FC group than in the control
group (P < 0.05) (Fig. 3). Cystometry revealed that the FC group had
a signiﬁcantly shorter mean ICI during saline infusion, comparedodium channel-a protein in the rat urinary bladder after three days of vehicle, ﬂu-
ing indicates 40 ,6-diamidino-2-phenylindole (DAPI)-positive nuclei, mineralocorticoid
the rat urinary bladder. MR and ENaC-a were localized at the rat urinary bladder
ps. Scale bar ¼ 500 mm.
S. Yamamoto et al. / Journal of Pharmacological Sciences 130 (2016) 219e225224with the control group (360.0 ± 50.8 s vs. 639.5 ± 138.0 s, respec-
tively; P < 0.05). The amiloride infusion did not cause an intra-
group change in the ICI of the control group. However, the
amiloride infusion signiﬁcantly prolonged the ICI in the FC group
compared with that in the FC group during the saline infusion
(538.4 ± 79.1 s vs. 360.0 ± 50.8 s, respectively; P < 0.01). No
signiﬁcant difference in the ICI was observed between the control
and FC groups during the amiloride infusion (635.0 ± 140.5 s vs.
538.4 ± 79.1 s, respectively) (Fig. 4A, B). The amiloride infusion did
not create any intra-group or inter-group differences in the MP
between the control and FC groups (Fig. 4C).3.5. The effect of MR blockade
After treatment with the vehicle, FC, or FC plus EPL, we evalu-
ated bladder function via cystometry. Cystometry revealed that the
FC group had a signiﬁcantly shorter mean ICI during the saline
infusion, compared with the control group. Co-administration of
EPL with FC extended the ICI compared with that of the FC group,
although the difference was not statistically signiﬁcant. Hence, the
ICI of the FCþ EPL group was not signiﬁcantly different from the ICI
of the control group (Table 2).
In addition, we examined MR and ENaC-a protein localization
and ENaC-a protein expression levels by western blotting. ENaC-a
protein expression in the FC group was signiﬁcantly higher than
that in the control group. Co-administration of EPL with FC slightly
prevented the up-regulation of ENaC-a, although not statistically
signiﬁcant (Fig. 5).
According to immunohistochemistry results, in all groups, both
MR and ENaC-a were localized only at the urothelium and not in
the smooth muscle or vessels (Fig. 6).4. Discussion
A previous study reported that MRs are expressed in the urinary
bladder of toads. MRs bind aldosterone and regulate unidirectional
transport of sodium from the mucosal phase to the serosal phase
via activated amiloride-blockade sodium channels (13). However,
MR expression in the mammalian urinary bladder is not well
studied. This is the ﬁrst study to reveal that functional MRs are
expressed in the rat urinary bladder epithelium. In this context, the
oral administration of FC (a potent synthetic MR agonist), elicited
frequent urination without affecting the bladder-to-body weight
ratio, blood pressure, or detrusor muscle contractile activity of rats.
Furthermore, this frequent urinationwas attenuated by intravesical
infusion of amiloride (an ENaC inhibitor). Co-administration of EPL
(a selective MR blocker) with FC tended to improve this frequent
urination.
In renal, colonic, and fetal lung alveolar type II epithelial cells,
aldosterone-bound MR is translocated into the nucleus, where it
regulates the expression and activity of ENaC (11,12). Furthermore,
ENaC is reported to have a mechanosensitive property in Caeno-
rhabditis elegans (19). ENaC is reportedly expressed in the rat and
rabbit urinary bladder epithelium and plays a role in the mecha-
nosensory transduction of the bladder by responding tomechanical
stretch during the urine storage phase (7,9,20). In addition, a
previous study reported that seven of nine patients with bladder
outlet obstruction and benign prostatic hyperplasia exhibited
involuntary detrusor contraction and increased ENaC expression in
the urinary bladder epithelium (10). Furthermore, the IPSS storage
symptom score is signiﬁcantly correlated with ENaC expression
levels (10). In our study, as expected, systemic FC administration
increased ENaC-a protein expression and induced frequent urina-
tion. This frequent urination was attenuated by intravesicalinfusion of amiloride (an ENaC inhibitor). Thus, upregulated ENaC
may play a role in FC-induced storage dysfunction.
To conﬁrm the involvement of MR, we co-administered FC and a
selective MR blocker, EPL. Blockade of MR signaling using EPL,
tended to ameliorate FC-induced storage dysfunction and
prevented the up-regulation of ENaC-a, although these differences
were not statistically signiﬁcant. These results further suggested
that the MR-ENaC pathway is involved in bladder function.
Furthermore, we demonstrated that MP did not change after FC
administration and/or amiloride infusion. Therefore, these ﬁndings
indicate that MR activation in the bladder epithelium affects ENaC
expressionwithout affecting the contractile activity of the detrusor
muscles; thus, this pathway may be an effective target for man-
aging storage symptoms.
Based on these ﬁndings, it appears logical that patients with
diseases that result in elevated aldosterone levels (e.g., primary
aldosteronism) would experience storage symptoms. Indeed, pa-
tients with primary aldosteronism experience nocturia, which is a
manifestation of storage symptoms. However, nocturia is caused by
a decrease in the kidneys' ability to concentrate urine, which is
induced by low serum potassium levels and which causes the
subsequent polyuria (21). Thus, although these patients may
exhibit bladder overactivity that is derived from pathological
changes in the epithelium, it is impossible to distinguish between
bladder overactivity and polyuria in these cases. Metabolic syn-
drome or obesity is also related to elevated serum aldosterone
levels or activation of the renineangiotensinealdosterone system
via obesity-associated insulin resistance or hypertension (22e24).
Associations between metabolic syndrome and lower urinary tract
symptoms have recently been reported. In particular, both basic
(25) and clinical research (26e28) have revealed a relationship
between metabolic syndrome and storage dysfunction. Therefore,
the MR-ENaC pathway might be a novel target for storage symp-
toms in these diseases.5. Conclusions
In conclusion, the MR protein is localized in the rat urinary
bladder epithelium, and the MR-ENaC pathway in the bladder
epitheliummight contribute to storage dysfunction (e.g., overactive
bladder) via these pathological mechanisms. This pathway may be
a novel therapeutic target for ameliorating storage symptoms.Conﬂicts of interest
The authors indicated no potential conﬂicts of interest.References
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